A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome

Hagen Blaszyk, Arndt Hartmann, Julie M. Cunningham, Daniel Schaid, Lester E. Wold, John S. Kovach, Steve S. Sommer

Research output: Contribution to journalArticle

42 Scopus citations

Abstract

Several retrospective studies have suggested p53 gene mutation as an adverse prognostic indicator in breast cancer patients, based on a selective growth advantage of p53 mutant cancer cells and their presumed resistance to current adjuvant therapy regimens. A cohort of 90 Caucasian midwestern breast cancer patients was analyzed prospectively (60 months of follow-up) with a rigorous mutation detection methodology. The presence of a p53 gene mutation was the single most adverse prognostic indicator for recurrence (p = 0.0032) and death (p = 0.0001), and was associated with poor response to both adjuvant (p = 0.0001) and palliative (p = 0.006) therapy. Analysis of the p53 gene with appropriate mutation detection methodology markedly improves the prediction of early recurrence, treatment failure, and death in breast cancer patients. (C) 2000 Wiley-Liss, Inc.

Original languageEnglish (US)
Pages (from-to)32-38
Number of pages7
JournalInternational Journal of Cancer
Volume89
Issue number1
DOIs
StatePublished - Jan 20 2000

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'A prospective trial of midwest breast cancer patients: A p53 gene mutation is the most important predictor of adverse outcome'. Together they form a unique fingerprint.

  • Cite this